SCHEMBL4953985

SCHEMBL4953985

CC(C)(C)P(C(C)(C)C)C(C)(C)C.OB(O)c1cccc2ccc3cc4ccccc4cc3c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.38
ERBB2 P04626 1/20 0.38
FYN P06241 1/20 0.38
MAOA P21397 1/20 0.38
ACHE P22303 1/20 0.38
AHR P35869 1/20 0.38
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
ALDH1A1 P00352 7/20 0.35
KDM4E B2RXH2 3/20 0.35
GAA P10253 2/20 0.35
SIGMAR1 Q99720 1/20 0.35
HSD17B10 Q99714 5/20 0.33
HPGD P15428 4/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
MAPT P10636 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HIF1A Q16665 2/20 0.32
CYP1B1 Q16678 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182202 0.91 CYP1A2 (0.44) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL829841 0.76 ALDH1A1 (0.46) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL28715754 0.75 ALDH1A1 (0.47) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL3790373 0.75 HSD17B10 (0.48) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL29709262 0.75 HSD17B10 (0.48) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL29243114 0.74 ALDH1A1 (0.46) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL31419512 0.72 ALDH1A1 (0.47) CYP1A2ERBB2FYNMAOAACHE
Lithium Ion SCHEMBL5621652 0.72 CYP1A2 (0.43) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL8681282 0.72 CYP1A2 (0.43) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL1871616 0.72 ALDH1A1 (0.47) CYP1A2ERBB2FYNMAOAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200535-A1 sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt ASAHI KASEI PHARMA CORPORATION (JP) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200535-A1 sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt S1PR1, S1PR2, S1PR4 CYP1A2 2532/4885ERBB2 3418/4885FYN 3034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.